DENTSPLY SIRONA Q1 EPS Forecast Lowered by Zacks Research

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Equities research analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for DENTSPLY SIRONA in a research note issued on Thursday, March 19th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $0.32 per share for the quarter, down from their previous estimate of $0.38. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Zacks Research also issued estimates for DENTSPLY SIRONA’s Q2 2026 earnings at $0.38 EPS, Q3 2026 earnings at $0.36 EPS, Q4 2026 earnings at $0.38 EPS, FY2026 earnings at $1.43 EPS, Q1 2027 earnings at $0.33 EPS, Q2 2027 earnings at $0.40 EPS, Q3 2027 earnings at $0.43 EPS, FY2027 earnings at $1.56 EPS and FY2028 earnings at $1.73 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. During the same period last year, the company earned $0.26 EPS. The business’s revenue was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, January 21st. Mizuho boosted their price target on DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Barrington Research increased their price objective on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. UBS Group reduced their price objective on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Finally, Barclays started coverage on DENTSPLY SIRONA in a report on Monday, December 8th. They issued an “underweight” rating and a $12.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $14.42.

DENTSPLY SIRONA Trading Down 2.8%

NASDAQ XRAY opened at $11.26 on Friday. The stock has a market cap of $2.25 billion, a PE ratio of -3.75, a PEG ratio of 1.36 and a beta of 0.97. DENTSPLY SIRONA has a 12 month low of $9.85 and a 12 month high of $17.18. The company’s 50-day moving average price is $12.68 and its 200-day moving average price is $12.34. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50.

Institutional Investors Weigh In On DENTSPLY SIRONA

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in DENTSPLY SIRONA by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock valued at $279,263,000 after purchasing an additional 869,566 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in shares of DENTSPLY SIRONA by 3.2% in the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock valued at $167,342,000 after purchasing an additional 458,744 shares during the period. AQR Capital Management LLC raised its stake in shares of DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC lifted its stake in DENTSPLY SIRONA by 0.9% during the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after acquiring an additional 92,868 shares during the period. Finally, Armistice Capital LLC boosted its holdings in shares of DENTSPLY SIRONA by 27.2% in the 4th quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock valued at $83,416,000 after acquiring an additional 1,562,000 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

Insiders Place Their Bets

In related news, Director Gregory T. Lucier acquired 27,555 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was purchased at an average cost of $14.24 per share, for a total transaction of $392,383.20. Following the purchase, the director directly owned 27,555 shares of the company’s stock, valued at $392,383.20. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director James D. Forbes bought 5,000 shares of the business’s stock in a transaction on Monday, March 9th. The stock was bought at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the purchase, the director directly owned 10,000 shares of the company’s stock, valued at $124,800. The trade was a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 70,000 shares of company stock worth $956,437 over the last quarter. Company insiders own 0.50% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.